Vyne Therapeutics Stock Investor Sentiment
| VYNE Stock | USD 2.70 0.12 4.65% |
About 55% of Vyne Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Vyne Therapeutics suggests that some traders are interested. The current market sentiment, together with Vyne Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Vyne Therapeutics stock news signals to limit their universe of possible portfolio assets.
Vyne |
Vyne Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vyne Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Vyne Therapeutics that are available to investors today. That information is available publicly through Vyne media outlets and privately through word of mouth or via Vyne internal channels. However, regardless of the origin, that massive amount of Vyne data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vyne Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vyne Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vyne Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vyne Therapeutics alpha.
Vyne Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by David Domzalski of 4429 shares of Vyne Therapeutics at 2.159 subject to Rule 16b-3 | 11/01/2024 |
2 | BioCryst Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates | 11/04/2024 |
3 | VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/07/2024 |
4 | VYNE Therapeutics initiated with a Buy at BTIG on II potential - Yahoo Finance | 11/19/2024 |
5 | Acquisition by David Domzalski of 01 shares of Vyne Therapeutics at 2.1 subject to Rule 16b-3 | 11/29/2024 |
6 | Acquisition by Bruno Anthony D of 20000 shares of Vyne Therapeutics at 2.7 subject to Rule 16b-3 | 12/05/2024 |
7 | VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | 12/23/2024 |
8 | Disposition of 24536 shares by David Domzalski of Vyne Therapeutics at 3.35 subject to Rule 16b-3 | 12/31/2024 |
9 | VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo | 01/06/2025 |
10 | Acquisition by Lepore Patrick G of 15000 shares of Vyne Therapeutics at 2.92 subject to Rule 16b-3 | 01/15/2025 |
11 | Insider Buying Patrick Lepore Acquires 15,000 Shares of VYNE Therapeutics Inc | 01/17/2025 |
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |